| Literature DB >> 27313880 |
Abstract
Capsaicinoids are bioactive nutrients present within red hot peppers reported to cut ad libitum food intake, to increase energy expenditure (thermogenesis) and lipolysis, and to result in weight loss over time. In addition it has shown more benefits such as improvement in reducing oxidative stress and inflammation, improving vascular health, improving endothelial function, lowering blood pressure, reducing endothelial cytokines, cholesterol lowering effects, reducing blood glucose, improving insulin sensitivity, and reducing inflammatory risk factors. All these beneficial effects together help to modulate cardiometabolic syndrome risk factors. The early identification of cardiometabolic risk factors can help try to prevent obesity, hypertension, diabetes, and cardiovascular disease.Entities:
Year: 2016 PMID: 27313880 PMCID: PMC4893589 DOI: 10.1155/2016/4986937
Source DB: PubMed Journal: J Nutr Metab ISSN: 2090-0724
Figure 1The structure of the capsaicinoids.
Scoville heat units of different chili pepper.
| Scoville heat units | Chili pepper |
|---|---|
| 16,000,000 | Pure capsaicin and dihydrocapsaicin |
| 9,100,000 | Nordihydrocapsaicin |
| 8,600,000 | Homodihydrocapsaicin and homocapsaicin |
| 2,000,000 | Common pepper spray |
| 1,001,304 | Naga-Bih Jolokia pepper |
| 100,000–350,000 | Habanero ( |
| 100,000–325,000 | Scotch bonnet ( |
| 100,000–225,000 | Birds eye pepper |
| 100,000–200,000 | Jamaican hot pepper |
| 100,000–125,000 | Carolina Cayenne pepper |
| 95,000–110,000 | Bahamian pepper |
| 85,000–115,000 | Tabiche pepper |
| 75,000–80,000 | Red amazon pepper |
| 75,000 | Chile-Today Red Amazon Powder, from Chile-Today Hot Tamale |
| 50,000–100,000 | Thai pepper ( |
| 50,000–100,000 | Chiltepin pepper |
| 40,000–58,000 | Piquin pepper |
| 40,000–50,000 | Super chili pepper |
| 40,000–50,000 | Santaka pepper |
| 30,000–50,000 | Cayenne pepper ( |
| 30,000–50,000 | Tabasco pepper ( |
| 15,000–30,000 | De Arbol pepper |
| 12,000–30,000 | Manzano pepper |
| 6,000–23,000 | Serrano pepper |
| 5,000–10,000 | Hot wax pepper |
| 2,500–8,000 | Santaka pepper |
| 2,500–5,000 | Jalapeño ( |
| 2,500–5,000 | Guajillo pepper |
| 1,500–2,500 | Rocotillo pepper |
| 1,000–2,000 | Pasilla pepper |
| 1,000–2,000 | Ancho pepper |
| 1,000–2,000 | Poblano pepper |
| 700–1,000 | Coronado pepper |
| 500–2,500 | Anaheim pepper |
| 500–1,000 | New Mexico pepper |
| 400–700 | Santa Fe Grande pepper |
| 100–1000 | Cubanelle pepper ( |
| 100–500 | Pepperoncini, pepper also known as Tuscan peppers, sweet Italian peppers, and golden Greek peppers |
| 100–500 | Pimento |
| 0 | Sweet bell pepper |
Source: http://www.chilliworld.com/FactFile/Scoville_Scale.asp.
Capsaicinoids effects on potential markers of weight management.
| Markers (number of positive studies/total studies reported) | Capsaicin/capsaicinoids dose | Potential biological effects |
|---|---|---|
| Energy expenditure ( | 3–30 mg/d | Increase in EE for 30 min [ |
|
| ||
| Lipid oxidation and fat loss (15/18 studies) | 1–30 mg/d | Increase in lipid oxidation and decreased abdominal/body fat [ |
|
| ||
| Lipolysis (1/1) | 2 mg | Tolerable dose, increased plasma FFA (2 hr and 2.5 hr), and glycerol (4 hr) concentrations [ |
|
| ||
| Appetite (7/9 studies) | 2–30 mg | Decrease in appetite, decrease in energy intake, and increase in satiety [ |
|
| ||
| Weight management markers (3/3) | 2 mg | Body indices (waist circumference, hip circumference, and WHR); appetite; lipolysis [ |
Cross reference.
Summary: capsaicinoids modulating CMS risk factors through different potential mechanism of action.
| CMS markers | Potential mechanism of action |
|---|---|
| Control of IGT/diabetes | Reducing carbohydrate absorption, improving insulin sensitivity, improving glucose utilization and metabolism, delaying glucose absorption, increase in fecal excretion of acidic sterols, decreasing fasting and postprandial hyperglycemia and improving glycemic control, increasing blood flow to insulin-sensitive tissues, adipose tissue lipolysis, and the catabolism of glucose and fatty acids but inhibiting fatty acid synthesis, and ameliorating oxidative stress [ |
|
| |
| Reduction of dyslipidemia | Antilipidemic effects: binding bile acids and inhibiting pancreatic lipase; plasma lipids, functionality of aorta including atherosclerotic plaque development, cholesterol absorption biomarker, mRNA levels of hepatic 3-hydroxyl-3-methylglutaryl CoA reductase, and cholesterol-7 |
|
| |
| Reduction of hypertension | Antihypertensive effects: direct vasodilators, calcium channel blockers, inhibiting the gene expression of COX-2, controlling the vascular tone through the release of calcitonin gene-related peptide (CGRP), substance P (SP), and neurokinin A, increase in intracellular calcium, which causes the release of several neuropeptides [ |
|
| |
| Attenuating body weight | Increased energy expenditure, increased lipid oxidation, reduced appetite, reduced abdominal adipose tissue levels, decreased body fat, pad weights of epididymal and prerenal adipose tissues, and reduced fat accumulation by downregulating PPAR |
|
| |
| Improving endothelial function | Improving endothelial function, inhibiting the transmembrane influx of calcium ions into cardiac and vascular smooth muscle, improving coronary vascular circulation, and decreasing expression of TRPV1 and cation influx [ |
|
| |
| Reduction in inflammation | Anti-inflammatory effects: lowering cytokines and C-reactive protein, reducing eNOS transcription, and depleting neurons of neurotransmitters, leading to reduction in pain sensation and blockade of inflammation [ |
Studies based on in vitro and in vivo studies and few human studies.